Current challenges in implementing cell-derived influenza vaccines: implications for production and regulation, July 2007, NIBSC, Potters Bar, UK

Vaccine. 2009 May 14;27(22):2907-13. doi: 10.1016/j.vaccine.2009.02.064. Epub 2009 Feb 27.

Abstract

A meeting was held at NIBSC, UK in July 2007 to discuss the implications of progress in the use of cell culture systems for the manufacture of vaccines against influenza. Issues discussed included the effect of using eggs and different cell types in strain selection, development of seed viruses to be used in production and the nature of the reagents to be used in determining vaccine potency. Future studies to progress the field were reviewed.

Publication types

  • Review

MeSH terms

  • Drug Approval*
  • Humans
  • Influenza Vaccines / adverse effects*
  • Influenza Vaccines / immunology*
  • Orthomyxoviridae / genetics
  • Orthomyxoviridae / growth & development*
  • Orthomyxoviridae / immunology*
  • Reassortant Viruses / genetics
  • Reassortant Viruses / growth & development*
  • Reassortant Viruses / immunology*
  • United Kingdom
  • Virus Cultivation / methods

Substances

  • Influenza Vaccines